2021 Fiscal Year Final Research Report
Construction of a model for predicting the therapeutic effect of cancer immunotherapy using a multiplex immunochemistry analysis system.
Project/Area Number |
19K18625
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 56030:Urology-related
|
Research Institution | Saitama Medical University (2020-2021) National Cancer Center Japan (2019) |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 腎細胞癌 / 免疫チェックポイント阻害薬 / バイオマーカー |
Outline of Final Research Achievements |
In this study, no predictors of treatment response to nivolumab-ipilimumab combination therapy in renal cell carcinoma patients were identified from the multiplex immunohistochemistry analysis system. Analysis of clinical data revealed that the neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), and C-reactive protein (CRP) were all predictive of response at the start of treatment. Furthermore CRP was found to be useful in predicting response after treatment initiation.
|
Free Research Field |
泌尿器癌
|
Academic Significance and Societal Importance of the Research Achievements |
進行腎細胞癌の治療戦略において免疫チェックポイント阻害薬は中心的な役割を担っている。しかし、治療効果を予測・反映する因子は確立していない。本研究結果は進行腎細胞癌の治療開始前または治療開始早期の治療効果予測に有用と考えられる。治療効果が予測できれば、個々の患者の状態にあわせた適切な治療選択をすることができる。
|